Dana-Farber Cancer Institute and Harvard Medical School
Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last three decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.
He is the recipient of many scientific and humanitarian awards including: the International Myeloma Workshop Waldenstrom’s Award; the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award; the American Association for Cancer Research Joseph H. Burchenal Award; the American Society of Hematology William Dameshek Prize; the Johns Hopkins Society of Scholars; election to the Institute of Medicine of the National Academy of Sciences and the Royal Colleges of Physicians and of Pathologists (UK); the American Society of Clinical Oncology David A. Karnofsky Award; the Hope Funds for Cancer Research Award of Excellence in Clinical Research; the Ron Burton Humanitarian Award; the Harvard Medical School Warren Alpert Foundation Prize; the American Cancer Society Medal of Honor; the Leonard P. Zakim Patient Advocacy Award; the Samuel Waxman Research Foundation David Workman Memorial Award; and the University of Miami Sylvester Cancer Center Annual Zubrod Memorial Award. He is a Fellow of the American Association for Cancer Research and the American Society of Clinical Oncology, and has served as President of the International Myeloma Society and President of the American Society of Hematology.
Dr. María-Victoria Mateos, MD, PhD, is Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Haematology Department.
She serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials especially in the smouldering myeloma setting and these trials have profoundly influenced current options for the management of these patient populations.
She has published over 250 original papers in international journals and her articles had received 29.452 citations (19268 since 2015) with a H index of 79 and 60 since 2015.
She is also a member of the IMWG (International MM Working Group), IMS (International MM Society), EHA and ASH. Among her invited presentations, she has contributed to the educational sessions of EHA 2012, ASH 2013, ASCO 2015, EHA 2016, ASCO and ASH 2017.
She has served on the ASH Scientific Committee on plasma cell diseases between 2015-2019 and on the EHA’s Scientific Program Committee and Advisory Board since 2013 until 2020 being chair of the Scientific Program Committee in 2019.
She has been Councillor on the EHA Board since 2015 for a four-year mandate, member of the Steering Committee for the Society of Hematologic Oncology (SOHO), member of the IMS board and member of the European School of Haematology (ESH) Scientific committee. She received the Briand Durie Award in 2019 recognizing excellence in myeloma research.
Philippe Moreau, MD, serves as Professor of Clinical Hematology and head of the translational research program in hematology and oncology, at the University Hospital of Nantes, France. Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.
Professor Moreau is the chairman of the Intergroupe Francophone du Myélome (IFM).
He is vice-president of International Myeloma Society (IMS) since 2019, and he is a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator or co-PI of many international randomized phase 3 clinical trials: Tourmaline (Ixazomib for relapsed myeloma), Aspire (Carfilzomib for relapsed myeloma), Endeavor (Carfilzomib for relapsed myeloma), Stratus (Pomalidomide for relapsed myeloma), Pollux (Daratumumab for relapsed myeloma), Arrow (weekly versus biweekly Carfilzomib for relapsed myeloma), Cassiopeia (Daratumumab for frontline therapy in transplant eligible patients) or Ikema (Isatuximab for relapsed myeloma).
He was a member of the organizing committee for the 2011 International Myeloma Workshop in Paris.
His research is widely published. Professor Moreau has authored or coauthored more than 300 peer-reviewed articles that have appeared in high impact factor journals including, the New England Journal of Medicine, Journal of Clinical Oncology, The Lancet, The Lancet Oncology, and Blood. He is a member of the editorial boards of Blood, and Blood Cancer Journal and is frequently invited to speak at international hematologic oncology meetings.
Professor Moreau received in 2018 the Robert A. Kyle lifetime achievement award.
Professor Hervé Avet-Loiseau is Head of the Laboratory for Genomics in Myeloma in the University Cancer Center of Toulouse since September 2012. Before, he was head of the Hematology Laboratory of the University Hospital of Nantes, France, a position he has held since 2008. He received his medical degree with a specialization in Pediatric Hematology in 1990. After pursuing a postdoctoral fellowship in the laboratory of Dr. Joe Gray in San Francisco, he moved into the area of Biological Hematology in 1995 and subsequently specialized in cytogenetics. He received his PhD in 1998 and became Professor of Hematology in 2001. Professor Hervé Avet-Loiseau is highly involved in the Intergroupe Francophone du Myélome (IFM), past Chairman, where he leads all biological studies. Most of these studies are based on the analysis of genetic/genomic abnormalities observed in malignant plasma cells using different technologies, including Fluorescence In-Situ Hybridization (FISH), gene expression profiling, single nucleotide polymorphism (SNP) arrays, and Next Generation Sequencing (NGS).
Dr. Castillo was born in Peru, received his medical degree in Mexico City, and completed his Internal Medicine and Hematology & Oncology training at the University of Massachusetts and Brown University, respectively. Dr. Castillo is an Associate Professor at Harvard Medical School and serves as the Clinical Director of the Bing Center for Waldenström Macroglobulinemia at the Dana-Farber Cancer Institute, and he sees approximately 1,000 patients with Waldenström Macroglobulinemia per year in his Clinic. Dr. Castillo is also the principal investigator in a series of innovative clinical trials evaluating highly effective non-chemotherapeutic approaches for patients with Waldenström macroglobulinemia. Dr. Castillo is a member of the NCCN Committee for Myeloma, Amyloidosis and Waldenström Macroglobulinemia. He has authored more than 250 peer-reviewed articles and has published his research in the New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology and Blood.
Dr Madhav Dhodapkar is the director of Winship Center for Cancer Immunology, Anise McDaniel Brock Chair, Georgia Research Alliance Eminent Scholar in Cancer Innovation and professor of Hematology and Medical Oncology in the Emory School of Medicine. He also co-leads the cancer immunology program at Winship Cancer Institute. Prior to moving to Emory in 2018, Dhodapkar served as chief of hematology, the Arthur H. and Isabel Bunker Professor of Medicine (Hematology), and professor of immunobiology at Yale University School of Medicine. An expert in cancer immunology, he also was co-director of the Cancer Immunology Program within the Yale Cancer Center. Dr Dhodapkar’s research focuses on how the immune system regulates the progression from precursor lesions to cancer as well as the mechanisms of treatment sensitivity and resistance to cancer immunotherapy and biology of dendritic cells.
Dr Dhodapkar earned his medical degree from the All India Institute of Medical Sciences in New Delhi, India, and completed his fellowship in oncology at the Mayo Clinic in Rochester, Minnesota. Prior to Yale, Dhodapkar served on the faculty at Memorial Sloan Kettering Cancer Center and The Rockefeller University in New York. He is a prior recipient of several awards including the NIH Director’s Transformative Research Award and the NCI Outstanding Investigator Award.
Meletios A. Dimopoulos, MD is Professor and Chairman of the Department of Clinical Therapeutics at the National and Kapodistrian University of Athens School of Medicine, Athens, Greece. He has been elected Vice Dean of the Medical School for the academic years 2007-2011 and Dean for the academic years 2011-2015. In February 2015 he was elected Rector of the National and Kapodistrian University of Athens for a 4 year term. He obtained his medical degree from the National and Kapodistrian University of Athens in 1985, completed a residency in internal medicine at the Royal Victoria Hospital, McGill University, Montreal, Canada and a fellowship in hematology/oncology at the University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Dr. Dimopoulos is a member of numerous scientific societies and has authored more than 1060 publications (July 2020) in peer-reviewed journals, as well as numerous abstracts and several textbook chapters primarily focusing on plasma cell dyscrasias and genitourinary and gynecologic cancers. He has more than 66000 citations and his h-index is 116 (Scopus) and more than 56800 citations and an h-index 108 (ISI). He is a journal reviewer for several journals including New England Journal of Medicine, Blood, Journal of Clinical Oncology, Haematologica, Leukemia, Cancer, European Journal of Haematology, Leukemia and Lymphoma etc. Dr. Dimopoulos was Associate Editor of the European Journal of Internal Medicine (2001-2007), is an Associate Editor of Current Hematologic Malignancy Reports and is an Editorial Board Member of the Journal of Clinical Oncology (2005-2008), of Haematologica, of Leukemia and Lymphoma, of Clinical Lymphoma, Myeloma and Leukemia (2018), of Expert Review of Hematology and of Blood Advances. Dr. Dimopoulos was an elected member of the Board of the International Myeloma Society (2013-2017).
Dr. Dimopoulos serves on the Scientific Advisory Boards of the International Myeloma Foundation, of the International Waldenstrom’s Macroglobulinemia Foundation and he is a member of the Board of the European Myeloma Network. Dr. Dimopoulos organized the XIth International Myeloma Workshop and the IVrth International Workshop on Waldenstrom’s Macroglobulinemia (Kos Island, Greece June 2007). In March 2013 Dr. Dimopoulos was elected as a member of the Board of the International Myeloma Society. Currently he is the chairman of the Greek Myeloma Study Group and of the Balkan Myeloma Study Group.
He is a recipient of the Robert A. Kyle Award for outstanding contributions to Waldenstrom’s macroglobulinemia (May 2003), a recipient of Waldenstrom’s award for Myeloma Research of the International Myeloma Society (March 2017), recipient of the CoMy Excellence Award (May 2017) and of the Robert Kyle Life Achievement Award (June 2019). In August 2017 he was given the title “Officier dans l’ Ordre des Palmes academiques” (Republique Francaise, Ministere de l’ Education Nationale). In May 2018 he was elected as membre associe etranger of the National Academy of Medecine of France. In January 2020 he received the MD Anderson Distinguished Alumnus Award.
Currently he is the Chairman of the Board of the Foundation of “Julia and Alexander N. Diomedes Botanic Garden” and he is a member of the Board of the National Greek Committee for UNESCO.
Hermann Einsele, MD, FRCP, is Full Professor of Internal Medicine and has been Director of the Department of Internal Medicine II of the University Hospital Würzburg, Germany, since 2004.
Following his medical training at the Universities of Tübingen, Manchester, and London, Professor Einsele became a research fellow in the Department of Haematology, Oncology, Rheumatology, and Immunology at the University of Tübingen, Germany. He was board certified in Internal Medicine in 1991 and in Haematology/Oncology in 1996. In 1999 was promoted as an Associate Professor. He is a visiting professor at the Fred Hutchinson Cancer Research Center in Seattle, WA, USA, and at the City of Hope Hospital, Duarte, CA, USA.
2011-2015 Hermann Einsele was Vice Dean of the Faculty of Medicine of the University of Würzburg, since 2015, he is Vice President of the University of Würzburg and since 2020 Chair of the German Society of Hematology and Medical Oncology (DGHO).
In 1999, he became Chairman of the German Study Group Multiple Myeloma. In 2003, he received the van Bekkum Award, the highest Annual European award for research in the field of stem cell transplantation. In 2011, he was elected as an Honorary Fellow of the Royal College of Pathologists (London) and in 2012 Nobel Lecturer Stem Cell Biology/ Transplantation, Nobel Forum Karolinska Institute. Since 2014, he was elected as a member of the Academy of Sciences and Literature, Mainz and 2017/2018/2019 as an ISI “Highly Cited Researcher” in the category Clinical Medicine.
Prof. Einsele is expert in the field of multiple myeloma, stem cell transplantation, CAR T cells, bi-specific antibodies and adoptive immunotherapy.
Prof. Francesca Gay, MD, PhD Myeloma Unit, Division of Hematology Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, via Genova 3, 10126 Torino, Italy firstname.lastname@example.org
Dr. Francesca Gay is Associate Professor in the University of Torino, Department of Molecular Biotechnology and Health Sciences, and works as hematologist at the Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Italy. She completed her medical degree in 2004 and her fellowship in hematology in 2008 at the University of Torino, Italy. She obtained her PhD in Medicine and Experimental Therapy in 2014.
She is involved in the design, development and coordination of phase I/II/III clinical trials for the treatment of multiple myeloma in tight collaboration with the European Myeloma Network (EMN and EMN Research Italy) and the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA). She is a member of the EMN young board. She is currently local principal investigator in several multi-center clinical trials. She worked on several international multicenter projects and data analyses.
Dr. Gay’s main research focuses on the diagnosis and the clinical and experimental treatment of patients with multiple myeloma and associated disorders, particularly of newly diagnosed patients eligible for autologous stem-cell transplantation. Her interests also include the use of new biological molecules, monoclonal antibodies, immunotherapeutic agents, CAR T Cells and stem-cell transplantation techniques.
She is a member of IMS, EMN, SIE, EHA and ASH. She is author and co-author of more than 100 papers published in peer reviewed journals, as well as reviewer for several journals including Lancet, Leukemia, Lancet Oncology, Lancet Hematology, and Haematologica. In 2019 she has been awarded the Bart Barlogie Young Investigator Award by the International Myeloma Society.
Dr. Irene Ghobrial is an Professor at Dana-Farber Cancer Institute (DFCI), Harvard Medical School, Boston, MA and an Associate member of the Broad Institute, Cambridge, MA. She is the Director of the Clinical Investigator research program at Dana-Farber Cancer Institute, co-director of the Center for Prevention of Progression (CPOP) and co-leader of the Blood Cancer Research Partnership (BCRP). She is also the director of the Michele & Stephen Kirsch Laboratory.
She received her medical degree from Cairo University School of Medicine, Egypt. She completed her internal medicine training at Wayne State University, MI, and her Hematology/Oncology subspecialty training at Mayo Clinic College of Medicine, MN.
Her research focuses on understanding mechanisms of tumor progression from early precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and Smoldering disease to symptomatic Multiple Myeloma (MM) and Waldenstrom Macroglobulinemia (WM). She specifically focuses on the role of the malignant bone marrow niche in regulating disease progression. She is interested in the development of new molecular/genomic markers that predict progression in precursor conditions which can identify patients who should be eligible for therapeutic interventions to prevent progression or potentially cure the disease at the early stages of the disease before clonal evolution occurs.
She authored or co-authored over 250 publications and book chapters and has received funding support from the National Cancer Institute as well as multiple foundations including Stand Up-to Cancer, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation and International Myeloma Foundation. She has received multiple awards including the Ken Anderson Young Investigator Award, Robert A. Kyle Award for Research in Waldenstrom Macroglobulinemia, and Mentor of the Year Award at DFCI.
Prof Graham Jackson, Professor of Clinical Haematology,
Freeman Hospital, The Newcastle Upon Tyne Hospitals
NHS Foundation Trust
Prof Jackson is a Consultant Haematologist at Newcastle Hospitals Trust, Newcastle upon Tyne and is a Professor of Haematology at Newcastle University.
He graduated from Cambridge and the Westminster School of Medicine. He gained his MRCP in 1986 and then moved to Newcastle University to undertake his MD, which he completed in 1992. Prof Jackson obtained his MRCPath in 1993, followed by his FRCP in 1999 and his FRCPath in 2000.
Throughout his career, Prof Jackson has received a number of awards, including a special fellowship to the European School of Haematology and European Community Fellowship to the European School of Oncology. He has won the Van Bekkum medal at the EBMT and has been awarded the BSH gold medal.
He is a former president of the BSH and the BSBMT and has served twice on the council of the RCPath. He has served on CTAAC and on the Blood wise clinical trials committee. He has been a director of Myeloma UK and scientific secretary for the UKMF.
He leads the myeloma service at the University of Newcastle upon Tyne/Newcastle Upon Tyne Hospitals trust. He has been CI on the MRC Myeloma 9 and 11 and is currently the CI for myeloma 11+and 14. He is part of the safety monitoring committee for all the MUK trials and previously was on the DMEC for the Endeavour and Clarion trials. His research interests focus on clinical trials and safety in the treatment of myeloma, development of long-term bone marrow transplant follow-up clinics, and the cytokine profile of acute and chronic graft-versus-host disease.
He has published over 200 peer reviewed papers as well as many book chapters and reviews.
Dr. Sigurdur Yngvi Kristinsson is a professor at the University of Iceland and the principal investigator for the iStopMM (Iceland screens, treats or prevents multiple myeloma) a nationwide screening study for MGUS. He did his fellowship in internal medicine and hematology at the Karolinska University Hospital and defended his thesis at the Karolinska Institutet in Sweden.
Current research group includes more than 20 people among those 7 PhD-students, a lab with 4 biologists, postdocs, 4 research nurses, and statisticians.
With over 100 papers published, Dr. Sigurdur Yngvi Kristinsson has received multiple grants and awards, including the Brian G.M. Durie Outstanding Achievement Award from International Myeloma Foundation in 2018.
Current position is Professor in Hematology at the University of Iceland.
Shaji K. Kumar, MD, is Consultant in the Division of Hematology and Professor of Medicine at Mayo Clinic Cancer Center in Rochester, Minnesota. He serves as Medical Director for the Mayo Clinic Cancer Center Clinical Research Office and Vice Chair for research in the Department of Medicine, Mayo Clinic.
Dr. Kumar received his medical degree from the All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by an internal medicine residency and a hematology/oncology fellowship at the Mayo Graduate School of Medicine in Rochester, Minnesota.
Dr. Kumar’s research focuses on the development of novel drugs and drug combinations for the treatment of myeloma. His laboratory focuses on understanding the role of bone marrow microenvironment in the development and progression of myeloma.
Dr. Kumar serves as Co-Chair of the NCI Myeloma Steering Committee as Chair of the NCCN Multiple Myeloma Guidelines Panel.
Alessandra Larocca, MD, PhD is a hematologist at the Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Italy. She studied Medicine at the University of Milano, and completed her residency in Hematology at the same institution. In 2014 she obtained her PhD in Pathology and Experimental Oncology at the University of Torino.
She is involved in the design, development and coordination of phase I/II/III clinical trials for the treatment of multiple myeloma in tight collaboration with the European Myeloma Network (EMN and EMN Research Italy) and the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA). She is currently local principal investigator in several multi-center clinical trials.
Dr. Larocca’s main research focuses on the diagnosis and the clinical and experimental treatment of patients with multiple myeloma and associated disorders, particularly of elderly patients. Her interests also include the use of new biological molecules, monoclonal antibodies, immunotherapeutic agents, CAR T Cells and stem-cell transplantation techniques.
She is a member of EMN, EHA and ASH. She is author and co-author of several papers published in peer reviewed journals.
Prof. Steven LE GOUILL, M.D., Ph.D. Professor of Hematology, University of Nantes, France.
CHU Hôtel Dieu
Service d’Hématologie Clinique
1, Place Alexis Ricordeau
F-44093 Nantes cedex
Prof. Steven Le Gouill heads the Hematology Department at Nantes Medical University, France. He is a member of the LYSA group where he is the chair of the scientific board and co-chairman of the Mantle cell lymphoma (MCL) committee. He is also involved in basic research in MCL (Team 10, INSERM UMR892, Nantes, France), his team investigates apoptosis dysregulations in MCL cells.
Prof. Le Gouill is 50 years old and graduated M.D. with specialization in Haematology from Nantes Medical University in 1999. He started his professional Haematology career at the Department of Nantes where he did his fellowship and where he became Assistant Professor and Associate Professor. He is a former Research Associate of the Department of medical oncology of Dana-Farber Cancer Institute (Harvard Medical School, Boston. USA) and graduated Ph.D. with specialization in “blood cells biology” from Paris VII University (France). Since 2010, he is Professor of Haematology at the Medical University of Nantes, France.
Prof Le Gouill received the French Society award in 2017 and published as first or corresponding authors in major peer-review journals (including New England Journal of Medicine, Journal of clinical oncology, Blood, Lancet Haematology, Annals of Oncology …)
OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2018)
DO NOT EXCEED FIVE PAGES.
NAME: LONIAL, Sagar
eRA COMMONS USER NAME (credential, e.g., agency login): SAGARLONIAL
POSITION TITLE: Professor of Hematology and Medical Oncology
INSTITUTION AND LOCATION DEGREE Completion Date FIELD OF STUDY
The Johns Hopkins University, Baltimore, MD B.A. 05/1989 Biology/Philosophy
University of Louisville School of Medicine, Louisville, KY M.D. 05/1993 Medicine
Baylor College of Medicine, Houston, TX Internship/
Residency 07/1996 Internal Medicine
Baylor College of Medicine, Houston, TX Chief Resident 07/1997 Internal Medicine
Emory University, Atlanta, GA Fellowship 07/2000 Hematology/Oncology
A. Personal Statement
I completed my Hematology-Oncology training at Emory University, and prior to that received my internal medicine training at the Baylor College of Medicine in Houston Texas. There, I spent an additional year as a Chief Medical Resident at the Ben Taub General Hospital as well as the Texas Heart Institute at St. Luke’s Hospital. My current title is professor. My previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen which was tested in a phase II clinical trial. More recently, I’ve focused on combinations of novel agents as therapy for myeloma using preclinical models that then allow for phase 1 translational trials leading to an interest in targeting 14-3-3 preclinically and working to overcome proteasome resistance. Additionally, I have led national, international, investigator initiated clinical trials, and NCTN trials through the cooperative groups as well as CTEP through the PTMA process. Many of these trials I have initiated have led to practice changing outcomes including trials that have led to the approval or 3 antibodies in MM (one in progress). My lab group has been funded by the MMRF, the Lymphoma Research Foundation, and the Leukemia and Lymphoma Society. The Clinical Myeloma program at Winship/Emory sees over 2000 individual multiple myeloma patients per year with a very broad catchment area that spreads to most of the southeast and has around 30% of patients who are African American, a patient population that is more predisposed to developing plasma cell disorders and one that is often under-represented in clinical trials and other preclinical studies.
a. Gu Y, Kaufman JL, Bernal L, Torre C, Matulis SM, Harvey RD, Chen J, Sun SY, Boise LH, Lonial S. MLN4924, an investigational NAE inhibitor, suppresses AKT and mTOR signaling pathway through up regulating REDD1 in human myeloma cells. Blood. 2014 Apr 8.
b. Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, Kaufman JL, Yacoub AM, Buadi FK, O’Brien T, Matous JV, Anderson DM, Emmons RV, Mahindra A, Wagner LI, Dhodapkar MV, Rajkumar SV Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. J Clin Oncol. 2020 Apr 10;38(11):1126-1137.
c. Lonial S, Kaufman J, Tighiouart M, Nooka A, Langston AA, Heffner LT, Torre C, McMillan S, Renfroe H, Harvey RD, Lechowicz MJ, Khoury HJ, Flowers CR, Waller EK. A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study. Clin Cancer Res. 2010 Oct 15; 16(20):5079-86.
B. Positions and Honors
Positions and Employment
1993 – 1996 Internship/Residency, Baylor College of Medicine, Houston, Texas
1996 – 1997 Chief Resident, Baylor College of Medicine, Ben Taub General Hospital, Houston, Texas
1996 – 1997 Attending Staff, Ben Taub General Hospital, Department of Internal Medicine Houston, TX
1997 Chief Resident, Department of Medicine, Baylor College of Medicine, St. Luke’s Episcopal Hospital, Houston, TX
1997- 2000 Fellow Hematology/Oncology, Emory University School of Medicine (SOM) Atlanta, GA
1999 – 2000 Chief Fellow, Emory University SOM, Winship Cancer Institute Atlanta, GA
2000 – 2011 Assistant Professor, Emory University SOM, Winship Cancer Institute, Atlanta, GA
2001 – Founder and Course Director Annual Updates in Hematology & Oncology Winship Cancer Institute Atlanta, GA
2003 – Director of Translational Research, B-cell Malignancy Program, Winship Cancer Institute of Emory University
2007 – 2009 Associate Director, Heme-Onc Fellowship Program, Emory University
2009 – 2015 Vice Chair of Clinical Affairs, Department of Hematology and Medical Oncology, Emory University SOM
2011 – Professor, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia
2015 – Executive Vice Chair of Clinical Affairs, Department of Hematology and Medical Oncology, Emory University School of Medicine.
2015 – Chief Medical Officer, Winship Cancer Institute of Emory University, Atlanta, GA
2015- Chair, Department of Hematology and Medical Oncology, Emory University SOM
Honors and Awards
1995 Houston Society of Internal Medicine – Best Resident in Internal Medicine
1996 Henry B. Macintosh Award
2005 MMRC Center of the Year Award
2012 MMRF recognition as one of 15 “MMRF Innovators”
2015 MMRF ‘Top 15 Innovator’ Award
2015 MilliPub Club Award, Emory University School of Medicine
2017 Lifetime Achievement Award for Outstanding Contributions, Indo-American Cancer Association
2019 COMY Multiple Myeloma Excellence Award for Clinical Science
Other Experience and Professional Memberships
1985 – 1989 The Adult Leukemia Service, P. J. Burke, Mentor, Johns Hopkins Oncology Center,
1989 – 1990 BMT Research Lab, Don Stevens, Mentor, Brown Cancer Center, Louisville, KY
1998 – 2000 Stem Cell Biology Lab, Edmund Waller, Mentor, Emory University SOM, Atlanta, GA
2000 – 2003 Blood Cell Therapy Lab, Emory University School of Medicine, Atlanta, GA
2001 – 2016 International Myeloma Society, Board of Directors
2016 – 2020 International Myeloma Secretary
2017 Co-Chair International Myeloma Workshop, New Delhi India
2003 – B-Cell Malignancy Lab, Emory University School of Medicine, Atlanta, GA
2007- ECOG Myeloma Committee Vice-Chair
2008- IMF Scientific Board of Advisors
2009- 2012 Center for International Blood & Marrow Transplant Research (CIBTMR) Committee: Co-Chair
C. Contribution to Science
1. My initial laboratory work focused on modulation of dendritic cell subsets in the context of autologous and allogeneic transplantation. The work arose from an observation of my Mentor that patients who received higher numbers of donor plasmacytoid dendritic cells had a higher relapse rate post allogeneic transplant, and this was associated with lower rates of chronic graft versus host disease. My lab work and translational work then focused on trying to modulate DC content of the autologous and subsequently the allogenic stem cell product and evaluate the impact on post-transplant events such as relapse and graft versus host disease. This work culminated in two different clinical trials and one laboratory-based paper, which are listed below.
a. Waller EK, Rosenthal H, Jones TW, Peel J, Lonial S, Langston A, Redei I, Jurickova I, Boyer MW. Larger Numbers of CD4bright Dendritic Cells in Donor Bone Marrow are Associated with Increased Relapse after Allogeneic Bone Marrow Transplantation. Blood 97(10): 2448-2456, 2001.
b. Lonial S, Bomberger C, Waller EK. Changes in the Pattern of TCR V Repertoire Expression after Bone Marrow Transplant is Linked to the HLA Haplotype in Humans. British Journal of Hematology. 113 (1): 224-230, 2001
c. Lonial S, Hicks M, Rosenthal H, Duenzl M, Feinstein B, Langston A., Redei I, Torre C, Cherry J, Waller EK. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant. 2004 Dec; 10(12):848-57.
d. Lonial S, Akhtari M, Kaufman J, Torre C, Lechowicz MJ, Flowers C, Sinha R, Khoury HJ, Langston AA, Waller EK. Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte Colony-Stimulating Factor Results in Fewer Plasmacytoid Dendritic Cells in the Graft and Enhanced Donor T Cell Engraftment with Th1 Polarization: Results from a Randomized Clinical Trial. Biol Blood Marrow Transplant. 2013 Mar;19(3):460-7. PMID: 23201472.
2. My research focus then shifted as my clinical interests moved towards drug development and signaling based treatment for patients with myeloma. Our clinical focus was on clinical trials and access to new agents in myeloma, and initially began with approval trials for bortezomib and lenalidomide, and then shifted towards early phase clinical trials for new drugs and agents. From a laboratory perspective, the work initially focused on methods by which to enhance sensitivity to proteasome inhibitors. We started using farnesyl transferase inhibitors (FTI’s) due to an initial suggestion that these agents could target ras/raf/mapk signaling, known important mediators of MM survival. What we learned was that their effects were on protein degradation, not just on ras signaling, and these observations led to clinical trials. We have additionally worked on the use of other targeted agents such as perifosine (Akt targeting) and MLN 4924 (NEDD 8 inhibitor) to further enhance the efficacy of proteasome-based treatments. Most recently I led an NCI sponsored PTMA program wherein we identified ways to test MLN 4924 in many diseases, and currently lead a trial in myeloma combining with bortezomib based on our preclinical paper.
a. David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S. The combination of the Farnesyl transferase inhibitor (Lonafarnib) and the proteasome inhibitor (Bortezomib) induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood. 2005 Dec 15;106(13):4322-9.
b. David E, Kaufman JL, Flowers CR, Schafer-Hales K, Torre C, Chen J, Marcus AI, Sun SY, Boise LH, Lonial S. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood. 2010 Sep 15.
c. Lonial S, Boise L. Farnesyl transferase inhibitors, autophagy and proteasome inhibition, Synergy for all the right reasons. Autophagy. 2011 Apr;7(4):448-9.
d. Gu Y, Xu K, Torre C, Samur M, Barwick BG, Rupji M, Arora J, Neri P, Kaufman J, Nooka A, Bernal-Mizrachi L, Vertino P, Sun SY, Chen J, Munshi N, Fu H, Kowalski J, Boise LH, Lonial S. 14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. Leukemia. 2018 Mar;32(3):744-751.
3. In addition to work in the laboratory and translational arena, my focus has been on building a clinical myeloma program that performs translational medicine and provides access to novel drugs for patients. As such, our program now sees over 1600 plasma cell patients over the course of a year and enrolls over 200 patients on clinical trials. We have been a part of clinical trials that are responsible for the approval of bortezomib, lenalidomide, carfilzomib, pomalidomide, panobinostat, and most recently the two monoclonal antibodies elotuzumab and daratumumab and a 3rd which is pending (Belantamab mafodotin) in myeloma. Additionally, I led the largest SMM clinical trial performed to date in ECOG-ACRIN which has changed the standard of care for SMM patients.
a. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005 Dec 1;106(12):3777-84.
b. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13;373(7):621-31.
c. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 9;387(10027):1551-60.
d. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207-221.
Complete List of Published Work in MyBibliography: https://www.ncbi.nlm.nih.gov/pubmed?term=Lonial%20S
D. Research Support
Ongoing Research Support
5U01CA217875-02 Fu (PI) 8/01/2017-7/31/2022
Systematic Discovery of Neomorph Protein-Protein Interactions in Cancer for Oncogenic Pathway Perturbation
The goals of this multi-investigator center grant are to identify candidate novel protein-protein interaction drug targets as part of the Cancer Target Discovery and Development (CTD²) Network.
MMRF-11-001 Lonial (PI) 12/16/2011 – 12/15/2021
Multiple Myeloma Research Foundation
MMRF-11-001: A Prospective, Longitudinal, Observational Study in Newly Diagnosed Multiple Myeloma (MM) Patients to Assess the Relationship between Patient Outcomes, Treatment Regimens and Molecular Profiles
Role: Institutional PI
5R01CA192844-05 Boise (PI) 12/23/2015-11/30/2020
The Role of CD86 in Multiple Myeloma
The goals of this grant are to determine the role and regulation of CD86 in myeloma cell survival. Current application is a supplement for this award.
MMRC Site Investment Grant 2018 Lonial (PI) 12/31/2017 – 12/30/2020
Multiple Myeloma Research Consortium
MMRF Answer Fund 2017 Boise (PI) 3/01/2018 – 03/31/2020
Multiple Myeloma Research Foundation
Transcriptional dysregulation in high risk myeloma.
Completed Research Support (selected – last 3 years)
Lonial (PI) 1/01/2017 – 12/31/2018
Multiple Myeloma Research Foundation
Epigenetic Mechanisms of Multiple Myeloma Pathogenesis and Evolution
C1605 Lonial (PI) 6/26/2013 – 6/26/2017
C16005: An Open-Label, Dose-Escalation, Phase I/II Study of the Oral Form on MLN9708, a Second-Generation Proteasome Inhibitor, Administered in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
MMY2002: An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are Double Refractory to a Proteasome Inhibitor and an IMiD
Winship Cancer Institute National Clinical Trials Network Lead Academic Participating Site
This is a national cooperative group clinical trials program with the goals of facilitating the rapid initiation and completion of cancer clinical trials and sustaining and increasing the level of engagement between Winship and the NCTN and its network groups in terms of scientific and administrative leadership as well as overall accrual to NCTN trials.
Giampaolo Merlini received his medical degree and specialized in Hematology and in Laboratory Medicine at the University of Pavia. He was trained by Prof. Jan Waldenström and Prof. Elliott Osserman in the study of monoclonal gammopathies and systemic amyloidosis. He founded and was the Director of the Center for Research and Treatment of Systemic Amyloidosis until 2016, University Hospital Policlinico San Matteo, and he is now the Director of Research of the University Hospital. He is Professor of Clinical Biochemistry, Department of Molecular Medicine, University of Pavia, Italy. He was President of the International Society of Amyloidosis from 2005 to 2010. He received several awards, including the Jan G. Waldenström Award from the International Workshop on Waldenström’s Macroglobulinemia in 2008, the 2017 Ham-Wasserman Lecture of the American Society of Hematology, the Robert Kyle Award from the International Workshop on Waldenström’s Macroglobulinemia in 2018, and the Jan G. Waldenström Award from the International Myeloma Society in 2019.
Dr. Merlini’s research interests include the pathogenesis, natural history, diagnosis and treatment of monoclonal gammopathies, in particular immunoglobulin light chain amyloidosis. His recent research focuses on the investigation of molecular mechanisms of cardiac damage, on biomarkers for assessing prognosis and response to therapy and on the development of novel therapeutic agents and treatment designed in the light of advances in the understanding of the molecular mechanisms of these diseases. He is principal investigator for several research projects in this field.
Nikhil C. Munshi, MD is the Kraft Family Chair and Professor of Medicine at the Harvard Medical School and the Director of Basic and Correlative Science, and Associate Director of the Jerome Lipper Myeloma Center at the Dana Farber Cancer Institute. He is an attending physician at the Brigham and Women’s Hospital, Harvard Medical School. Dr. Munshi received his medical degree from the S.S.G. Hospital and M.S. University, Baroda India. He completed a Research Fellowship in Medical Oncology at the Johns Hopkins Oncology Center in Baltimore, Maryland, and a clinical fellowship in hematology/oncology at the Indiana University Medical Center. Prior to joining Dana Farber, Dr. Munshi was Professor of Medicine and Director of the Clinical Gene Transduction Laboratory at the University of Arkansas.
Dr. Munshi’s research focus spans both basic sciences to understand genomic changes in myeloma and elucidate molecular mechanisms driving the genomic instability in cancer, to translational approaches directed at improving diagnosis and prognosis as well as therapeutics. Dr Munshi’s clinical interests include CAR T-cell therapy in multiple myeloma and developing novel targeted therapeutics including novel antigen-directed and immune effector cell therapy/vaccine approaches.
He has over 500 peer-reviewed publications and book chapters. Dr Munshi has mentored over 70 junior faculty, post-doctoral fellows, medical residents, as well as medical and undergraduate students. A number of them are now independent scientists, physicians, and professionals. His grant support has included Program Project and SPORE grants from National Institutes of Health, and VA Research grants. He is the current President of the International Myeloma Society. He has received number of Awards including a Leukemia Society of America Scholar in Translational Research Award, the Dr. B.C. Roy National Award by the president of India in 2016 and the prestigious “Waldenstrom’s Award” for Most Distinguished Lifetime Achievement in Myeloma Research in 2013.
Dr Bruno Paiva, PharmD, PhD, is a research fellow of the Departments of Haematology and Immunology at the Clinica Universidad de Navarra and CIMA, Pamplona, Spain. He is also the Director of the Flow Cytometry Core of the University of Navarra.
Dr Paiva’s main area of expertise is the multiparameter flow cytometry analysis of haematological malignancies. His research focuses on improving the differential diagnosis, risk stratification, and monitoring of patients with monoclonal gammopathies (MGUS), smouldering and symptomatic multiple myeloma, Waldenström’s macroglobulinaemia, and amyloidosis. He is an author or co-author of several publications in peer-reviewed journals.
Noemi Puig, MD, PhD earned her medical degree from the Universidad Complutense in Madrid and she completed her residency in Internal Medicine and Hematology at the University Hospital La Fe in Valencia, Spain. She completed a 3-year fellowship in Lymphoma, Myeloma and Autologous Stem Cell Transplantation at the Princess Margaret Hospital in the University of Toronto, in Toronto, Canada. She earned a doctoral degree at the Medicine Department of the University of Salamanca, in Spain, with a thesis entitled “Optimization and Critical Analysis of Minimal Residual Disease Monitoring with ASO RQ-PCR in Patients with Multiple Myeloma and Comparison with Multiparameter Flow Cytometry”. Dr. Puig currently serves as a Consultant Physician at the Hematology Department in the University Hospital of Salamanca. She also works in the Flow Cytometry Laboratory of the University Hospital of Salamanca, where she is responsible for the studies developed by the Spanish Myeloma Group.
Dr. Puig is a member of the Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) and the Spanish Myeloma Group (GEM) as well as of the EuroFlow Group.
Dr. Puig´s main research interests include the role of multiparameter flow cytometry and of mass spectrometry in diagnosis, risk stratification and minimal residual disease monitoring in patients with monoclonal gammopathies. She is an author or co-author in several research articles, reviews and book chapters.
Dr. Raje is a Professor of Medicine at Harvard Medical School, the director of the Center for Multiple Myeloma and the Rita Kelley Chair in Oncology at the Massachusetts General Hospital Cancer Center. She is a physician scientist with a primary focus on multiple myeloma and related plasma cell disorders. Dr. Raje has focused on developing new promising therapies for Multiple Myeloma. Her laboratory efforts are aimed at identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and designing trials to specifically harness these. She is the co-chair of the NCI steering committee for Multiple Myeloma and a board member of the International Myeloma Society.
After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at Dana-Farber Cancer Institute (DFCI), Dr. Paul Richardson joined the Jerome Lipper Myeloma Center in 1999, was appointed Clinical Director in 2001, and led the development of several first-generation novel drugs including bortezomib, lenalidomide and pomalidomide for the treatment of multiple myeloma. Subsequent studies have focused on next generation novel drugs including panobinostat and second-generation proteasome inhibitors including ixazomib. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma, as well as isatuximab and more broadly, antibody drug conjugates including belantamab mafodotin, as well as other immunotherapeutic strategies. In addition to these agents, he is leading the development of melflufen, a targeted cytotoxic and a first-in-class small molecule inhibitor selinexor, which inhibits XPO-1, a key nuclear export protein, as well as first-in-human studies of cereblon E3 ligase modulators (so called CELMoDs) for the treatment of relapsed and refractory myeloma.
Over the last decade, his major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (so-called RVD), and its incorporation as part of the Intergroup Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with RVD. This regimen has generated an unprecedented response rate, leading to its adoption in this international study, as well as others in the United States and elsewhere. This particular trial incorporates genomic and proteomic evaluation to establish a future platform for tailored therapy and the optimal positioning of stem cell transplant, with results anticipated in 2021-22. Furthermore, RVD has been established as a backbone to which next generation agents are being added, including elotuzumab, daratumumab and isatuximab, as well as panobinostat.
He has published extensively, having authored or co-authored over 400 original articles and 330 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the Editorial Boards of leading journals, he is prior Chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. He was also a member of ASCO Hematologic Malignancies Subcommittee for the required one-year term, and then for one year on the ASCO Internet Cancer Information Committee during 2017. He was appointed Chair of the Alliance Myeloma Committee in 2011 and continues in this role.
Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, and The Tisch Outstanding Achievement Award for Clinical Research, as well an honorary Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway in 2012. He was also a co-recipient of the Accelerator Award for contributions to clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year Award in 2009, followed by a second award for Center of the Year in 2017. He was ranked by Thomson Reuters Science Watch amongst the top 19 investigators at DFCI for the most highly cited research in 2016. He was the co-recipient of the ASH Ernest Beutler Prize for clinical science and translational research in the development of proteasome inhibition as an effective treatment strategy for multiple myeloma in 2015; the COMY Award for MM research (Paris, France) in 2016, and the prestigious IMF Robert A. Kyle Lifetime Achievement Award in 2017, and the Morse Research Award in 2019.
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute, Charlotte, North Carolina
Saad Zafar Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani joined the faculty of the Levine Cancer Institute in July 2013; he also currently holds an academic appointment as Clinical Professor of Medicine at the University of North Carolina-Chapel Hill School of Medicine. Previously, Dr. Usmani served as an Assistant Professor of Medicine at the University of Arkansas for Medical Sciences in Little Rock, Arkansas and Director of Developmental Therapeutics at the Myeloma Institute for Research & Therapy.
Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a Fellow of the American College of Physicians. He holds membership in several professional societies, including the International Myeloma Working Group, the SWOG Myeloma Committee, the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the American Society of Bone Marrow Transplantation. Dr. Usmani has served as the Track Leader on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, and he is a member of the ASH Committee on Plasma Cell Neoplasia and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani is on the editorial review board of numerous medical journals, has authored/co-authored more than 150 peer-reviewed research manuscripts and 200 abstracts at national and international meetings. Active in clinical and translational research, Dr. Usmani has research interests focus on plasma cell disorders—in particular, high-risk multiple myeloma.
Elena Zamagni MD, PHD, is Assistant Professor of Hematology at the University of Bologna, Italy. She received her medical degree from University of Bologna, where she also served her residency in haematology. She got PHD in Clinical Hematology at the University of Bologna in May 2005.
Her research interests include areas related to multiple myeloma, in particular on the role of high dose therapy with stem cell support , of prognostic factors and of imaging techniques.
She has published over 100 papers in peer-reviewed journals, mainly in the field of plasma cell dyscrasia. She has contributed to the educational session of the Italian Society of Haematology (SIE) and American Society of Clinical Oncology (ASCO). She is abstracts reviewer for SIE, EHA and ASH. She is part of the editorial board of Frontiers in Oncology since 2019. She is an active member of the board of the GIMEMA and European Myeloma Network (EMN) working party and she has cooperated in the Scientific secretary and as principal investigator in several national randomized trials in multiple myeloma. She is a member of the Italian Society of Haematology and of the International Myeloma Working Group. She is serving on the EHA’s Scientific Program Committee since 2017. She is responsible for the career development committee within the International Myeloma Society since 2019.
Sonja Zweegman, MD, PhD, is head of the Department of Hematology, Amsterdam UMC in Amsterdam, the Netherlands. She is vice-chaiman of the HOVON Myeloma Working Group.
Her clinical research is focused on the improvement of the treatment of patients with Multiple Myeloma. She is the principal investigator of several (inter)national clinical trials in the elderly aiming at personalized treatment based on the level of frailty. In order to reach that goal, she investigates whether functional geriatric assessments and biological markers of frailty, such as senescence and sarcopenia, are better predictors for the feasibility of therapy. Furthermore, she co-leads the myeloma translational research group, which is embedded within the Department of Hematology, in order to integrate scientific research with care. The research is dedicated to improve immune therapy of Multiple Myeloma. Firstly, by investigating the mechanism of action of immune therapy, being exemplified by revealing the long term immune-regulatory effects of anti-CD38 monoclonal antibodies, and the biological background of immune therapy resistance. Secondly, by developing novel treatment strategies, such as dual CAR-T cell therapy. She is a co-author of more than 200 peer-reviewed papers and several book chapters.
It’s been a busy quarter for the @MM_Hub! Last quarter, the @MM_Hub held a SC meeting, provided coverage of #ESHMM2020, #COMy20, and #ASH20, and gained new supporters. Read more here: https://loom.ly/blwJ4G0 #mmsm
CONGRESS | #ESHMM2020 | 🎧 Listen to our podcast with the Steering Committee member @H_Einsele, @Uni_WUE, where he discusses new immunotherapeutic strategies in multiple #myeloma ➡️ https://buff.ly/3plmkVM #mmsm
📽️ Which patients with smoldering multiple myeloma would you enrol in a clinical trial? Watch the @MM_Hub interview with the steering committee member @mvmateos to find out: https://buff.ly/3jZdbiB #mmsm #ESHMM2020
This site place cookies on your machine for reasons including keeping track of your preferences, collecting aggregated statistics to analyze how our site is used, and to show you ads tailored to your interests. I have read and agree to the ESH GENERAL TERMS AND CONDITIONS OF USE for the ESH “5th Translational E-Conference on Multiple Myeloma” virtual platform. ACCEPT
Privacy, Cookies Policy, General Terms and Conditions of Use
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.